Christopher Liu Profile - Lucid Capital Analyst
46 Followers
Christopher Liu's Stock Coverage
| NVCTNuvectis Pharma | Aug 05, 2026 | BUY | Reiterated | $34.00 | 3Ratings | +19.43% | ||
| CRDFCardiff Oncology | Jun 05, 2026 | BUY | Reiterated | $4.00 | 2Ratings | -44.45% | ||
| NXTCNextCure | Jun 02, 2026 | BUY | Reiterated | $25.00 | 2Ratings | +36.45% | ||
| FTHFaeth Therapeutics | May 28, 2026 | BUY | Initiated | $50.00 | 1Ratings | -50.40% | ||
| ACTUActuate Therapeutics, Inc. | May 18, 2026 | BUY | Reiterated | $5.00 | 1Ratings | -89.90% | ||
| RLMDRelmada Therapeutics | Mar 02, 2026 | BUY | Initiated | $14.00 | 1Ratings | -41.00% | ||
| TVRDTvardi Therapeutics | Feb 04, 2026 | BUY | Upgraded | $6.00 | 2Ratings | -73.00% | ||
| ANLAdlai Nortye Ltd. Sponsored ADR | Jan 29, 2026 | BUY | Initiated | $11.00 | 1Ratings | +33.80% | ||
| AAPGAscentage Pharma Group International Unsponsored ADR | Dec 15, 2025 | BUY | Initiated | $50.00 | 1Ratings | -52.80% | ||
| IPHAInnate Pharma | Oct 23, 2025 | BUY | Initiated | $8.00 | 1Ratings | -31.50% |
Disclaimer: TipRanks collects analysts’ ratings and price targets by scanning publicly available reports on financial websites and by receiving reports from analysts, firms, or customers. The information and statistics displayed might not be accurate, complete, or up-to-date. The analyst ratings provided are the sole responsibility of the source publication. TipRanks holds no liability over the analysts' information, price targets, ratings, or opinions expressed. See how TipRanks ranks experts and calculates performance.
Send Us Reports
If you receive reports that you think we are missing, we will thank you with a free Ultimate upgrade!
Learn More >Christopher Liu activity FAQ
What is the performance of Christopher Liu's recommendations?
The percentage of profitable recommendations made by Christopher Liu is 41.35%, and the average return per transaction is 5.80%.
What stocks does Christopher Liu cover?
What was Christopher Liu's most profitable rating?
Christopher Liu’s most profitable rating was a buy on Nurix Therapeutics stock on Nov 02, 2023. The return on the trade was 340.50%.
Where can I see a list of stock analyst ratings?
You can see a list of daily stock analyst ratings here.
What are the most recommended stocks by analysts?
You can see a list of the most recommended stocks by analysts here
